Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection

Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14(1):156-164.e3.

Publication Type:

Journal Article

Authors:

Gerber, Lynn; Estep, Michael; Stepanova, Maria; Escheik, Carey; Weinstein, Ali; Younossi, Zobair M.

Source:

Clin Gastroenterol Hepatol, Volume 14, Issue 1, p.156-164.e3 (2016)

Keywords:

Adult, Aged, Antiviral Agents, Benzimidazoles, Biomarkers, Blood Chemical Analysis, Cytokines, Enzyme-Linked Immunosorbent Assay, Fatigue, Female, Fluorenes, HCV, Hepatitis C, Chronic, Humans, IL10, Male, Middle Aged, PDGF, Retrospective Studies, Ribavirin, sofosbuvir, TNF, Treatment Outcome

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/26241510

Export Citation:

RIS Format

Top